Key milestone positions ART6043 as the most advanced Pol-theta inhibitor in clinical development; the potentially first-in-class program is ...

DNA polymerase theta (Pol θ) orchestrates a distinct, error-prone route of double-strand break (DSB) repair known as microhomology-mediated end joining (MMEJ) or theta-mediated end joining (TMEJ).

Illustration of fork-MMEJ and BIR pathways in repairing single-ended DNA double-stranded breaks at broken replication forks, highlighting ATR-mediated regulation of the transition between these two ...

DNA repair proteins act like the body's editors, constantly finding and reversing damage to our genetic code. Researchers have long struggled to understand how cancer cells hijack one of these ...

Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations. This is an ASCO ...

The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 -- Artios Pharma Limited ("Artios"), a biopharmaceutical ...

The MarketWatch News Department was not involved in the creation of this content. -- Potential first-in-class, and industry-leading DNA polymerase Theta (Pol ) inhibitor, ART6043 demonstrated an ...